Relugolix–Estradiol–Norethindrone Acetate (Myfembree)

Canada’s Drug Agency (CDA-AMC) recommends that Myfembree should be reimbursed by public drug plans for the treatment of heavy menstrual bleeding (HMB) from uterine fibroids (UFs) in patients in the premenopausal stage if certain conditions are met. Myfembree should only be covered to treat patients who are aged 18 years or older who have HMB from UFs and who have not reached menopause. Myfembree should only be reimbursed if prescribed by clinicians with expertise in diagnosing and managing UFs and the cost is not more than the least costly regimen of leuprolide acetate with or without add-back therapy (hormonal therapy to reduce negative side effects). When first prescribed, Myfembree should be reimbursed for 6 months, after which response to treatment should be assessed. The drug should not be reimbursed if used in combination with a gonadotropin-releasing hormone agonist or antagonist, upon successful surgery or medical procedure to treat UFs, pregnancy, menopause, or if significant bone loss occurs.